About Eddingpharm
Eddingpharm is a company based in Shanghai (China) founded in 2001. Eddingpharm has raised $56 million across 2 funding rounds from investors including Orbimed, Taikang Fund and H&Q Asia Pacific. Eddingpharm has completed 1 acquisition, including ACT Biotech. Eddingpharm offers products and services including Anti-Infection Drugs and Cardiovascular Therapies.
- Headquarter Shanghai, China
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eddingpharm
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$56 M (USD)
in 2 rounds
-
Latest Funding Round
$32 M (USD), Series B
Nov 08, 2017
-
Investors
Orbimed
& 4 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eddingpharm
Eddingpharm offers a comprehensive portfolio of products and services, including Anti-Infection Drugs and Cardiovascular Therapies.
Drugs for anti-infection treatments are developed and distributed to address clinical demands in China
Therapies for cardiovascular diseases are provided through global partnerships and local commercialization efforts
Funding Insights of Eddingpharm
Eddingpharm has successfully raised a total of $56M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $32 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eddingpharm
Eddingpharm has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, Taikang Fund and H&Q Asia Pacific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Buyouts are targeted via private equity by H&Q Asia Pacific.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Eddingpharm
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eddingpharm
Eddingpharm has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ACT Biotech.
Investment portfolio details for Eddingpharm
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule kinase inhibitors for cancer therapy are developed.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Eddingpharm
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Eddingpharm
Detailed financials for Eddingpharm
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eddingpharm Comparisons
Peer comparison for Eddingpharm
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eddingpharm
Detailed competitors of Eddingpharm
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eddingpharm
Complete news archive for Eddingpharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eddingpharm
Eddingpharm was founded in 2001 and raised its 1st funding round 9 years after it was founded.
Eddingpharm is headquartered in Shanghai, China.
Eddingpharm is a funded company, having raised a total of $56M across 2 funding rounds to date.
Eddingpharm was founded in 2001 and is headquartered in Shanghai, China. Operations in the biopharmaceutical sector are centered on critical illnesses with unmet needs. Global technologies and products are introduced via licensing and acquisitions, encompassing clinical trials, manufacturing, and sales. Production facilities are maintained to international standards, while research and development efforts target new pharmaceuticals. Commercial activities are guided by data analysis and compliance protocols.
Eddingpharm offers Anti-Infection Drugs and Cardiovascular Therapies.
Eddingpharm has made 1 acquisition, including ACT Biotech.
Eddingpharm has 5 investors. Key investors include Orbimed, Taikang Fund, H&Q Asia Pacific, Sequoia Capital, and Domain Associates.